My guest for Episode 79 of The Startup Playbook Podcast is Bill Ketelbey, the CEO and Managing Director of Actinogen Medical.

After deciding to leave his executive career in a large Pharmaceutical company, Bill was searching for a meaningful endeavour to be involved in.

That quest led him to join biotech startup, Actinogen, which has created a novel way to treat Alzheimer’s, the most common form of Dementia, which is the second leading cause of death of Australians contributing to 5.4% of all deaths in males and 10.6% of all deaths in females each year.

Bill is trained a neurosurgeon, and a former medical director of Pfizer Australia and New Zealand, where he ran all medical operations across the Australasian region.

His team of researchers was involved in all phases of human research for most of the Pfizer products that subsequently came to market. Bill has helped launch household drug names such as Viagra, Lipitor and the current market-leading Alzheimer’s drug, Aricept.

Bill is now the CEO and Managing Director of Actinogen, a clinical stage ASX listed Australian biotechnology startup focused on the development of novel treatments for Alzheimer’s Disease and other major age-related neurodegenerative disorders.

In this interview we talk about:

• The process in taking a biotech product to market
• Investment opportunities in Biotech
• Commercialising research in Australia
• Preparing for opportunities

PLAYBOOK MEDIA – Growth through Data-Driven Storytelling

THE E-COMMERCE PLAYBOOK

ACCELEPRISE AUSTRALIA

STARTUP PLAYBOOK HUSTLE APPLICATION 

Feedback/ connect/ say hello: 
Rohit@startupplaybook.co
@playbookstartup (Twitter)
@rohitbhargava7 (Twitter – Rohit)
Rohit Bhargava (LinkedIn)

Podcast: Play in new window | Download | Embed

Subscribe: RSS